Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901-Reference-Cited by-同舟云学术

Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901

Published:2017-09 Issue: Volume:111 Page:38-42
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Morikawa Naoto,Inoue Akira,Sugawara Shunichi,Maemondo Makoto,Harada Toshiyuki,Harada Masao,Fujita Yuka,Katoh Terufumi,Yokouchi Hiroshi,Watanabe Hiroshi,Usui Kazuhiro,Suzuki Toshiro,Sakakibara-Konishi Jun,Nagai Hiroki,Kanbe Mariko,Nukiwa Toshihiro

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference21 articles.

1. Cancer statistics;Jemal;CA Cancer J. Clin.,2008

2. Lung cancer;Herbst;N. Engl J. Med.,2008

3. Cancer statistics;Greenlee;CA Cancer J. Clin.,2000

4. Japan Clinical Oncology Group, Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer;Noda;N. Engl. J. Med.,2002

5. Phase III study comparing Amrubicin plus cisplatin with Irinotecan plus cisplatin in the treatment of extensive-disease small-cell Lung cancer: JCOG 0509;Satouchi;J. Clin. Oncol.,2014

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline;Journal of Clinical Oncology;2023-12-10

2. Creation of an Integrated Clinical Trial Database and Data Sharing for Conducting New Research by the Japan Lung Cancer Society;Haigan;2023-06-20

3. Creation of an Integrated Clinical Trial Database and Data Sharing for Conducting New Research by the Japan Lung Cancer Society;JTO Clinical and Research Reports;2022-05

4. Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases;Molecules;2022-04-11

5. The contributory roles of histone deacetylases (HDACs) in hematopoiesis regulation and possibilities for pharmacologic interventions in hematologic malignancies;International Immunopharmacology;2021-11